Glucagon-like peptide 2 prevents down-regulation of intestinal multidrug resistance-associated protein 2 and P-glycoprotein in endotoxemic rats

• Verfasst von: Arana, Maite Rocío [VerfasserIn]
• Verfasst von: Rigalli, Juan Pablo [VerfasserIn]
• Titel: Glucagon-like peptide 2 prevents down-regulation of intestinal multidrug resistance-associated protein 2 and P-glycoprotein in endotoxemic rats
• Verf.angabe: Maite Rocío Arana, Guillermo Nicolás Tocchetti, Felipe Zecchinati, Ana Sofía Londero, Camila Dominguez, Virginia Perdomo, Juan Pablo Rigalli, Silvina Stella Maris Villanueva, Aldo Domingo Mottino
• E-Jahr: 2017
• Jahr: 23 August 2017
• Umfang: 10 S.
• Fussnoten: Gesehen am 16.07.2018 ; Im Titel ist "P" in P-glycoprotein kursiv geschrieben
• Titel Quelle: Enthalten in: Toxicology
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1973
• Jahr Quelle: 2017
• Band/Heft Quelle: 390(2017), Seite 22-31
• ISSN Quelle: 1879-3185
• DOI: doi:10.1016/j.tox.2017.08.007
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cytokines
• Sach-SW: GLP-2
• Sach-SW: LPS
• Sach-SW: Mrp-2
• Sach-SW: Oxidative stress
• Sach-SW: P-gp
• K10plus-PPN: 1577646452

Abstract

Multidrug resistance-associated protein 2 (Mrp2, ABCC2) and P-glycoprotein (P-gp, ABCB1) constitute essential components of the intestinal biochemical barrier that prevent incorporation of food contaminants, drugs or toxic metabolites into the blood stream. Endotoxemia induced in rats by administration of bacterial lipopolysaccharide (LPS) results in elevated intestinal permeability and toxicity of xenobiotics in part associated with down-regulation of expression and activity of Mrp2 and P-gp. We evaluated the protective effect of glucagon-like peptide 2 (GLP-2), a peptide hormone with enterotrophic properties, on Mrp2 and P-gp alterations induced by single i.p. injection of LPS (5mg/kg b.wt.) to rats. Two different protocols of GLP-2 administration, namely prevention and reversion, were examined. The prevention protocol consisted of 7s.c. injections of GLP-2 (125μg/kg b.wt.) administered every 12h, starting 60h before LPS administration. The reversion protocol consisted of 2 doses of GLP-2, starting 3h after LPS injection. Intestinal samples were collected 24h after LPS administration and expression (protein and mRNA) and activity of Mrp2 were evaluated in proximal jejunum whereas those of P-gp were studied in ileum. GLP-2 completely neutralized down-regulation of expression of Mrp2 and P-gp and loss of their respective activities induced by LPS under prevention protocol. GLP-2 was also able to prevent internalization of both transporters from the apical membrane of the enterocyte to intracellular compartments, as detected by confocal microscopy. LPS induced an increase in IL-1β and oxidized glutathione tissue levels, which were also counterbalanced by GLP-2 administration. In contrast, the reversion protocol failed to attenuate Mrp2 and P-gp down-regulation induced by LPS. We conclude that GLP-2 can prevent down-regulation of intestinal expression and activity of Mrp2 and P-gp in endotoxemic rats and that IL-1β and oxidative stress constitute potential targets of GLP-2 protective effects.